ID | CMV viral load (IU/mL) | Treatment duration | Reduction or suspension of therapy weeks after GCV/VGCV | Side effect | Sensorineural hearing loss | Neuro-development†| ||
---|---|---|---|---|---|---|---|---|
Before GCV/VGCV | 6Â weeks after GCV/VGCV | Â | at birth | last visit | at 2Â years | |||
1 | 51,761 |  < LoD* | 6 weeks | None | None | None | None | No delay |
2 | 64,649 |  < LoD | 6 months | Suspension (4 W, 6–11 W) | Elevated transaminases | Both ears | No change | Mild |
3 | 88,674 |  < LoD | 6 months | None | None | Right ear | No change | No delay |
4 | 150,000 |  < LoD | 6 weeks | None | None | None | None | Mild |
5 | 87,688 | 5,099 | 3Â months | None | None | None | None | No delay |
6 | 10,994 | 7,535 | 4 months | Suspension (3 W, 9–11 W) Reduction (4–8 W) | Neutropenia | None | None | Mild |
7 | 116,600 | 31,975 | 6 months | Suspension (9–10, 12–17 W) reduction (4–8 W) | Neutropenia | None | None | Mild |
8 | 271,309 | 280,000 | 3Â months | None | None | None | None | Mild |
9 | 18,445 | 1250 | 6Â weeks | None | None | Both ears | No change | Mild |
10 | N.A§ | 2149 | 6 weeks | None | None | Both ears | No change | Mild |
11 | 167,250 | 199,125 | 10 months | Suspension (2, 6–7, 29–32 W) | Neutropenia, Elevated transaminases | Right ear | No change | Moderate |